Preferred Label : Senicapoc;
NCIt definition : An orally bioavailable inhibitor of the calcium-activated potassium channel KCa3.1
(Gardos channel; KCNN4; IK-1; SK4), with potential anti-inflammatory and immunomodulatory
activities. Upon oral administration, senicapoc targets, binds to and inhibits KCa3.1.
KCa3.1 regulates membrane potential and calcium signaling in a variety of cells including
erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium,
epithelia, and proliferating vascular smooth muscle cells and fibroblasts. The inhibition
of KCa3.1 may prevent erythrocyte dehydration in sickle cell disease, reduce fluid
secretion, fluid retention and inflammation in the lungs in acute respiratory distress
syndrome (ARDS), and reduce inflammation and immune responses in various other diseases
such as neuroinflammation in Alzheimer's disease. Senicapoc exhibits good brain penetration.;
UNII : TS6G201A6Q;
InChIKey : SCTZUZTYRMOMKT-UHFFFAOYSA-N;
CAS number : 289656-45-7;
Molecule name : PF-05416266; ICA-17043;
Chemical formula : C20H15F2NO;
Origin ID : C76882;
UMLS CUI : C2699287;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
